Healing of the bone with anti-fracture drugs

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 11, 2013, Pages 1441-1447

  Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anabolics; Anti fracture drugs; Antiresorptives; Bone healing; Regulatory requirements

Indexed keywords

ALENDRONIC ACID; AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCITONIN; DENOSUMAB; ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

BONE DENSITY; BONE MINERALIZATION; BONE REGENERATION; BONE REMODELING; BONE STRENGTH; BONE TISSUE; BONE TURNOVER; CALLUS; FRACTURE HEALING; FRAGILITY FRACTURE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RADIUS FRACTURE; REVIEW;

ANABOLIC AGENTS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; FRACTURE HEALING; FRACTURES, BONE; HUMANS;

EID: 84880093429     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.801959     Document Type: Review

References (64)

1. Einhorn TA, Laurencin CT, Lyons K. Fracture repair: challenges, opportunities, and directions for future research. J Bone Joint Surg Am 2008;90:438-42
2. Corrales LA, Morshed S, Bhandari M, Miclau T III. Variability in the assessment of fracture-healing in orthopaedic trauma studies. J Bone Joint Surg Am 2008;90:1862-88
3. Goldhahn J, Mitlak BH, Aspenberg P, et al. Critical issues in translational and clinical research fort he study of new technologies to enhance bone repair. J Bone Joint Surg Am 2008;90:43-7
4. Goldhahn J, Scheele WH, Mitlak BH, et al. Clinical evaluation of medicinal products for acceleration of fracture healing in patient with osteoporosis. Bone 2008;43:343-7
5. Goldhahn J, Beaton D, Ladd A, et al. Recommendation for measuring clinical outcome in distal radius fractures-a core set of domains for standardized reporting in clinical practice and research. In press
6. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med 2011;9:66-75
7. Cox G, Einhorn TA, Tzioupis C, Giannoudis PV. Bone turnover markers in fracture healing. J Bone Joint Surg Br 2010;92:B329-34
8. Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 2011;12:2533-52
9. Aspenberg P. Drugs and fracture repair. Acta Orthop 2005;76:741-8
10. Bukata SV. Systemic administration of pharmacological agents and bone repair: what can we expect. Injury 2011;42:605-8
11. Jorgensen NR, Schwarz P. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 2011;9:149-55
12. Einhorn TA. Can anti-fracture agents heal fractures? Cln Cases Miner Bone Metab 2010;7:11-14
13. Goldhahn J, Féron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012;90:343-53
14. Brandi ML. Drugs and bone healing. Expert Opin Investig Drugs 2012;1:1169-76
15. Wase AW, Solewski J, Rickes E, Seidenberg J. Action of thyrocalcitonin on bone. Nature 1967;214:388-9
16. Chesnut CH III, Silverman S, Adriano K, et al. A randomized trial of nasal salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
17. Paavolainen P, Taivainen T, Michelsson JE, et al. Calcitonin and fracture healing. An experimental study on rats. J Orthop Res 1989;7:100-6
18. Schatzker J, Chapman M, HàEri GB, et al. The effect of calcitonin on fracture healing. Clin Orthop 1979;141:303-6
19. Meller Y, Shaikin-Kestenbaum R, Shany S, et al. Parathyroid hormone, calcitonin, and vitamin D metabolites during normal fracture healing in humans. Clin Orthop 1984;183:238-45
20. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 2011;8:81-91
21. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6
22. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
23. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
24. Dempster DW. Exploiting and bypassing the bone remodelling cycle to optimize treatment of osteoporosis. J Bone Miner Res 1997;12:1152-4
25. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-73
26. Im GI, Qureshi A, Kenney J, et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-15
27. Follet H, Li J, Phipps RJ, et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007;40:1172-7
28. Plotkin LI, Lezcano V, Thostenon J, et al. Connexin 43 is required for the antiapoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008;23:1712-21
29. Naidu A, Dechow PC, Spears R, et al. The effect of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:5-13
30. Goodship E, Walker PC, McNally D, et al. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994;5:S53-5
31. Peter CP, Cook WO, Nunamaker DM, et al. Effect of alendronate on fracture healing and bone remodelling in dogs. J Orthop Res 1996;14:74-9
32. Li J, Mori S, Kaji Y, et al. Concentration of bisphosphonate (icandronate) in callus area and its effectson fracture healing in rats. J Bone Miner Res 2000;15:2042-51
33. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture reèair differently in ovariectomzed rats. J Bone Miner Res 2002;17:2237-46
34. Bauss F, Schenk RK, Hort S, et al. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 2004;50:25-34
35. Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007;22:867-76
36. Amanata N, He LH, Swain MV, Little DG. The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study. Med Eng Phys 2008;30:843-7
37. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196-208
38. Yu YY, Lieu S, Hu D, et al. Site specific effects of zoledronic acid during tibial and mandibular fracture repair. PLoS One 2012;7:e31771
39. Matos MA, Tannuri U, Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010;11:7-12
40. Kinov P, Tivchev P, Doukova P, Leithner A. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomized study. Arch Orthop Belg 2006;72:44-50
41. Hilding M, Aspenberg P. Local preoperative treatment with bisphosphonate improves the fixation of total knee prostheses. Arch Orthoped 2007;78:795-9
42. Solomon HMC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in oldr adults. Osteoporos Int 2009;20:895-901
43. Moroni A, Faldini C, Hoang-Kim A, et al. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007;89:96-101
44. Rozental TD, Vasquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate theraèy. J Hand Surg Am 2009;34:595-602
45. Colon-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2010;22:2329-36
46. Harding AK, W-Dahl A, Geijer M, et al. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop 2011;82:465-70
47. Stuermer EK, Sehmisch S, Rack T, et al. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in the rat. Langenbecks Arch Surg 2010;395:163-72
48. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
49. Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 2012;5:153-63
50. Alkhiari YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731-41
51. Raghavan P, Christofides E. Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes 2012;5:39-45
52. Peichl P, Holzer LA, Maier R, Olzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011;93:1583-7
53. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide fort he acceleration of fracture repair in humans: a prospective, randomized, double-blind study for 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14
54. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
55. Habermann B, Kafchitsas K, Olender G, et al. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic model of fracture healing. Calcif Tissue Int 2010;86:82-9
56. Frost HM. A Brief review for orthopaedic surgeons: fatigue damage (microdamage) in bone (its determinants and clinical implications). J Orthop Sci 1998;3:272-81
57. Hashimoto T, Shigetomi M, Ohno T, et al. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by valcularized bone transplantation. Calcif Tissue Int 2007;81:232-9
58. Aspenberg P, Wermelin K, Tengwall P, Fahlgren A. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats. Acta Orthop 2008;79:111-15
59. Birke O, Schindeler A, Ramachandran M, et al. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphophonates in the treatment of congenital pseudoarthrosis of the tibia. J Child Orthop 2010;4:507-17
60. Doi Y, Miyazaki M, Yoshiiwa T, et al. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model. Bone 2011;49:777-82
61. Larsson S, Fazzolari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg 2012; Epub ahead of print
62. Yu NY, Schindeler A, Tagil M, et al. Application of BMPs and bisphosphonates in improving bone fracture healing. Front Biosci 2012;4:2647-53
63. Li HF, Zhou CC, Li JH, et al. The effects of combined human parathyroid hormone 81-349 and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 2012;23:1463-74
64. Black DM, Bilezikian JP, Ensrud KE, et al. PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65